Bevacizumab in Combination With Irinotecan for Malignant Gliomas
- Determine the safety of bevacizumab and irinotecan hydrochloride in patients with
recurrent or refractory grade 3 or 4 malignant gliomas.
- Determine the activity of this regimen, in terms of progression-free survival, in these
OUTLINE: Patients receive bevacizumab and irinotecan hydrochloride every 2 weeks. Treatment
continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 68 patients will be accrued for this study.
Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
James J. Vredenburgh, MD
Duke Cancer Institute
United States: Food and Drug Administration
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|